|
Kurt Briner works as an independent consultant to the pharmaceutical and biotech industries and is a board member of OM Pharma, Switzerland, Progenics Pharmaceuticals Inc, US, and GALENICA SA, Switzerland. From 1988 to 1998, he was president and CEO of Sanofi Pharma, France. He has been chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Mr Briner holds a Diploma of the Commercial Schools of Basel and Lausanne, Switzerland.
Mr Briner was elected to the Board of Novo Nordisk A/S in 2000 and re-elected several times, most recently in 2007. His term as a board member expires in March 2008.
Mr Briner is a Swiss national, born on 18 July 1944. | 